CA2997652A1 - Novel therapeutic use of fgf19 - Google Patents

Novel therapeutic use of fgf19 Download PDF

Info

Publication number
CA2997652A1
CA2997652A1 CA2997652A CA2997652A CA2997652A1 CA 2997652 A1 CA2997652 A1 CA 2997652A1 CA 2997652 A CA2997652 A CA 2997652A CA 2997652 A CA2997652 A CA 2997652A CA 2997652 A1 CA2997652 A1 CA 2997652A1
Authority
CA
Canada
Prior art keywords
muscle
fgf19
mice
mass
fgf19 polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2997652A
Other languages
English (en)
French (fr)
Inventor
Emmanuelle FOUILLOUX-MEUGNIER
Hubert Vidal
Jerome Ruzzin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Institut National de Recherche pour lAgriculture lAlimentation et lEnvironnement
Universite Claude Bernard Lyon 1
Vestlandets Innovasjonsselskap AS
Original Assignee
Institut National de la Recherche Agronomique INRA
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Claude Bernard Lyon 1
Bergen Teknologioverforing AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Claude Bernard Lyon 1, Bergen Teknologioverforing AS filed Critical Institut National de la Recherche Agronomique INRA
Publication of CA2997652A1 publication Critical patent/CA2997652A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA2997652A 2015-06-25 2016-06-24 Novel therapeutic use of fgf19 Abandoned CA2997652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305990.2A EP3108893A1 (en) 2015-06-25 2015-06-25 Novel therapeutic use of fgf19
EP15305990.2 2015-06-25
PCT/EP2016/064671 WO2016207354A1 (en) 2015-06-25 2016-06-24 Novel therapeutic use of fgf19

Publications (1)

Publication Number Publication Date
CA2997652A1 true CA2997652A1 (en) 2016-12-29

Family

ID=53498933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997652A Abandoned CA2997652A1 (en) 2015-06-25 2016-06-24 Novel therapeutic use of fgf19

Country Status (5)

Country Link
US (1) US10695403B2 (enExample)
EP (2) EP3108893A1 (enExample)
JP (1) JP6761929B2 (enExample)
CA (1) CA2997652A1 (enExample)
WO (1) WO2016207354A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
SG11201903697WA (en) * 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
JP2020100591A (ja) * 2018-12-21 2020-07-02 味の素株式会社 筋質向上剤
CN112057606B (zh) * 2020-09-14 2023-09-19 上海市儿童医院 Fgf19在治疗和/或预防脓毒症诱发的器官损伤的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126852A1 (en) * 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
KR100506786B1 (ko) * 1997-11-25 2005-08-08 제넨테크, 인크. 섬유아세포 성장인자-19
KR20080108487A (ko) * 2006-02-28 2008-12-15 트르스티스 오브 보스톤 유니버시티 대사 조절인자 및 그의 용도
CN102656266B (zh) * 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
WO2013006486A2 (en) * 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases

Also Published As

Publication number Publication date
EP3108893A1 (en) 2016-12-28
WO2016207354A1 (en) 2016-12-29
JP2018519366A (ja) 2018-07-19
JP6761929B2 (ja) 2020-09-30
EP3313430B1 (en) 2020-11-18
US10695403B2 (en) 2020-06-30
EP3313430A1 (en) 2018-05-02
US20180369331A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
EP3313430B1 (en) Novel therapeutic use of fgf19
Master et al. Effects of dietary supplementation in sport and exercise: A review of evidence on milk proteins and amino acids
Sobiś et al. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity
De Koster et al. Relationship between serum adiponectin concentration, body condition score, and peripheral tissue insulin response of dairy cows during the dry period
Sanderson The epidemic of canine obesity and its role in osteoarthritis
Pilch et al. Changes in the lipid profile of blood serum in women taking sauna baths of various duration
Ishioka et al. Diurnal variations of serum leptin in dogs: effects of fasting and re-feeding
Yan et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus
JP6027386B2 (ja) 筋量増加剤
Kim et al. Health-promoting effects of bovine colostrum in Type 2 diabetic patients can reduce blood glucose, cholesterol, triglyceride and ketones
Kawao et al. Roles of the vestibular system in obesity and impaired glucose metabolism in high-fat diet-fed mice
Silva et al. Physical exercise, inflammatory process and adaptive condition: an overview
Miller et al. Dietary stimulation of the endogenous somatotropic axis in weaner and grower-finisher pigs using medium chain triglycerides and cysteamine hydrochloride
Kavanagh et al. Neonatal and fetal exposure to trans-fatty acids retards early growth and adiposity while adversely affecting glucose in mice
Oświęcimska et al. Chemerin serum levels in girls with anorexia nervosa
AU2019470336B9 (en) Agonist of Tacr2
Peterson Time-Restricted Eating: Effects on Body Weight and Cardiometabolic Health
KR102523844B1 (ko) Lgi3 유래 펩타이드를 유효성분으로 포함하는 고지혈증 및 지방간의 예방, 치료, 또는 개선용 조성물
Mori et al. Selective β3-adrenoceptor agonist reduces energy intake and elevates GDF15 levels in lean and diet-induced obese mice
Wray-Cahen et al. Porcine somatotropin alters insulin response in growing pigs by reducing insulin sensitivity rather than changing responsiveness
PEI et al. Research progress of current situation of sarcopenia and the preventive effect of protein on it
Gorji et al. 8 Weeks Pilates Training Effects on Fetuin-A Levels and Anthropometric Indicators in Sedentary Overweight Women.
Liu et al. Effect of Hypoxic Exercise on Adipose Tissue Hypoxia in Insulin-Resistant Rats.
Khodamoradi et al. Exercise Training and Obesity: The Role of Semaphorin 3E/Plexin D1 Axis: A Brief Review
Bruder TUM School of Life Sciences

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220916